Related Experiment Video

Updated: Jun 16, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Inhibition of cancer cell growth by anti-Tn monoclonal antibody MLS128

Noriyuki Morita1, Yukiko Yajima, Hideki Asanuma

  • 1Department of Applied Biochemistry, Tokai University School of Engineering, Hiratsuka, Kanagawa, Japan.

Bioscience Trends
|January 28, 2010
PubMed

Insights

Anti-Tn antibodies like MLS128 show therapeutic potential by targeting tumor-associated carbohydrate antigens. This antibody inhibited cancer cell growth, offering new avenues for carcinoma treatment.

Area of Science:

  • Oncology
  • Immunology
  • Glycobiology

Background:

  • Tumor-associated carbohydrate antigens (Tn-antigens) are exposed on epithelial cancers.
  • These antigens serve as sensitive markers for carcinoma detection.
  • Therapeutic strategies targeting tumor antigens are under investigation.

Purpose of the Study:

  • To investigate the therapeutic potential of antibodies targeting Tn-antigens.
  • To evaluate the efficacy of the anti-Tn monoclonal antibody MLS128 in cancer treatment.

Main Methods:

  • MLS128 was characterized for its binding epitope (three consecutive Tn-antigens).
  • The effect of MLS128 on cancer cell growth was assessed.
  • Cell surface glycoproteins bound by MLS128 were identified.
  • Changes in growth factor receptor expression following MLS128 treatment were analyzed.

Main Results:

  • MLS128 binds to a specific Tn-antigen epitope (GalNAcalpha-Ser/Thr).
  • MLS128 treatment significantly inhibited colon and breast cancer cell proliferation.
  • MLS128 targets 110-210 kDa cell surface glycoproteins.
  • MLS128 down-regulated insulin-like growth factor-I receptor and epidermal growth factor receptor in colon cancer cells.

Conclusions:

  • Anti-Tn antibodies, such as MLS128, demonstrate significant therapeutic potential against epithelial cancers.
  • MLS128-mediated inhibition of cancer cell growth may involve the down-regulation of key growth factor receptors.
  • This study highlights the promising role of anti-Tn antigen antibodies in cancer therapy.

More Related Videos

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...